Alcobra (ADHD) Issues Update on FDA Communications Regarding MEASURE Study
Alcobra Ltd. (NASDAQ: ADHD), an emerging pharmaceutical firm focused on the development of novel medications to treat cognitive disorders such as Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced earlier today that it has received a full clinical hold notice from the U.S. Food and Drug Administration’s Division of Psychiatry Products regarding its phase III clinical study of Metadoxine Extended Release (MDX) for the treatment of ADHD in adult patients. The letter indicates that the FDA hold in in response to electrophysiological neurologic findings in previously submitted long-term animal studies of Metadoxine. The FDA has recommended that Alcobra…